We believe iCAD, Inc. (ICAD), a provider of innovative cancer detection and targeted therapy solutions, has the potential to double over the next twelve months and triple by the end of 2015. Multiple near-term catalysts will accelerate iCAD's top-line growth and position the company to return to GAAP profitability in the next 2-3 quarters, potentially as early as Q4. Given that iCAD's stock is cheap by various valuation metrics, undiscovered, and under-owned, we feel strongly that shares have minimal downside and substantial upside into both year-end and also throughout both 2014 and 2015.
Only subscribers can access this article, which is part of the PRO research library covering 3,609 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: